van Herpen, Carla ML
Radboud University Medical Center
3 papers on CoChatORCID 0000-0001-5130-5451
Most cited papers
- Verified
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 640
- Verified
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer
Brummelen, E. M. J., Huijberts, S., Herpen, C., Desar, I., Opdam, F., Geel, R., Marchetti, S., Steeghs, N., Monkhorst, K., Thijssen, B., et al. (2021) · The Oncologist
Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies
Cited by 32
- Verified
The Early Effect of Sunitinib on Insulin Clearance in Patients with Metastatic Renal Cell Carcinoma
Thijs, A. M. J., Tack, C. J., van der Graaf, W. T. A., Rongen, G. A., & van Herpen, C. M. L. (2016) · British Journal of Clinical Pharmacology
Metabolism, Diabetes, and CancerRenal cell carcinoma treatment
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free